Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 7/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL3413247 | 0.98 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL3414603 | 0.98 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL8110 | 0.98 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL3416954 | 0.98 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL11798390 | 0.95 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL20485928 | 0.95 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL1370888 | 0.95 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL9214447 | 0.95 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL7204509 | 0.95 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL10868999 | 0.95 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119410750-A | Kit and method for simultaneously capturing gene expression, chromatin openness and mitochondrial DNA information at single cell level and application thereof | 中山大学 | 2025-02-11 | — | — | CN | disclosed |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-117883596-A | T of hypoxia response 1 -T 2 Switchable MRI contrast agent, preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-04-16 | — | — | CN | disclosed |
| EP-4329773-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | Astrocyte Pharmaceuticals, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117241803-A | Purine nucleosides, intermediates and methods of making the same | 阿斯特罗赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117069723-A | Refining method of pharmaceutical grade adenine | 江西阿尔法高科药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069723-A | Refining method of pharmaceutical grade adenine | 江西阿尔法高科药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116782885-A | Solid delta 9 Tetrahydrocannabinol (delta) 9 -THC) composition | 康纳化学有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112437811-B | Recombinant NAD synthetase, gene and application thereof | 邦泰生物工程(深圳)有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022232810-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-1594882-B1 | PROCESS FOR PREPARING BRANCHED RIBONUCLEOSIDES FROM 1, 2-ANHYDRORIBOFURANOSE INTERMEDIATES | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-101360748-A | c-MET inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-02-04 | — | — | CN | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
| EP-1594882-A1 | PROCESS FOR PREPARING BRANCHED RIBONUCLEOSIDES FROM 1, 2-ANHYDRORIBOFURANOSE INTERMEDIATES | Merck & Co., Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072090-A1 | PROCESS FOR PREPARING BRANCHED RIBONUCLEOSIDES FROM 1, 2-ANHYDRORIBOFURANOSE INTERMEDIATES | MERCK & CO. INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-0684979-B1 | LUBRICANT COMPOSITIONS CONTAINING COMPLEXES OF ALKOXYLATED AMINE, ACID, AND ADENINE | EXXON RESEARCH ENGINEERING CO (US) | 1997-07-23 | — | — | EP | disclosed |
| EP-0684979-A1 | LUBRICANT COMPOSITIONS CONTAINING COMPLEXES OF ALKOXYLATED AMINE, ACID, AND ADENINE. | EXXON RESEARCH ENGINEERING CO (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994019437-A1 | LUBRICANT COMPOSITIONS CONTAINING COMPLEXES OF ALKOXYLATED AMINE, ACID, AND ADENINE | EXXON RESEARCH & ENGINEERING COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5290460-A | Friction resistant compounds | EXXON RESEARCH & ENGINEERING CO. (US) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | PI4KA 2529/4885PI4K2B 3214/4885PI4K2A 2877/4885 |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | DUT, RNGTT, DPYD | PI4KA 3965/4885PI4K2B 4266/4885PI4K2A 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.